| | Placebo | MFGM | P-value |
---|
Serum components |
AST, IU/L | Baseline | 17.7 ± 1.5 | 17.1 ± 0.6 | |
4 weeks | 17.6 ± 0.8 | 16.6 ± 0.6 | P = 0.354 |
ALT, IU/L | Baseline | 14.3 ± 1.8 | 12.9 ± 1.3 | |
4 weeks | 12.4 ± 1.1 | 11.9 ± 1.0 | P = 0.880 |
Glucose, mg/dL | Baseline | 96.6 ± 2.1 | 95.5 ± 3.1 | |
4 weeks | 94.3 ± 2.0 | 97.7 ± 2.5 | P = 0.092 |
Triglyceride, mg/dL | Baseline | 99.4 ± 9.8 | 95.3 ± 10.5 | |
4 weeks | 92.5 ± 11.1 | 95.8 ± 9.2 | P = 0.397 |
Total cholesterol, mg/dL | Baseline | 187.9 ± 7.6 | 179.9 ± 7.7 | |
4 weeks | 177.7 ± 6.6 | 177.3 ± 7.4 | P = 0.387 |
Blood components |
WBCs, 102/μL | Baseline | 49.6 ± 4.1 | 46.7 ± 3.5 | |
4 weeks | 41.9 ± 3.2 | 46.4 ± 2.9 | P = 0.164 |
RBCs, 104/μL | Baseline | 503.1 ± 8.3 | 508.4 ± 8.9 | |
4 weeks | 494.0 ± 11.6 | 520.9 ± 11.1 | P = 0.013 |
Hemoglobin, mg/dL | Baseline | 15.1 ± 0.2 | 15.3 ± 0.2 | |
4 weeks | 14.8 ± 0.2 | 16.0 ± 0.3 | P < 0.001 |
- MFGM Milk fat globule membrane, AST Aspartate aminotransferase, ALT Alanine aminotransferase, WBCs White blood cells, RBCs Red blood cells
- Blood was collected from an intermediate vein of the forearm after an overnight fast. The serum samples were analyzed at SRL Inc. (Tokyo, Japan). The numbers of WBCs and RBCs, as well as the hemoglobin concentrations were measured with an automatic hemocytometer (Celltac MEK-5258, Nihon Kohden, Tokyo, Japan)
- Values are mean ± SEM of 14 subjects. Differences in study endpoints between interventions were analyzed by using a linear mixed model, with group, period, period baseline, and the interaction of group and period as fixed effects; and subject as a random effect. When the model showed a significant intervention effect, pairwise comparison between interventions was performed via Bonferroni analysis. Changes were considered significant if P < 0.05